ISS-Ⅲ期合并1q获得或17p缺失双打击对新诊断多发性骨髓瘤预后的不良影响
该回顾性研究纳入270例新诊断多发性骨髓瘤患者,将ISS-Ⅲ期、1q获得/扩增和17p缺失定义为打击因素。携带两种及以上打击因素者(31.1%)中位PFS仅14.5个月、OS仅18.4个月,显著差于单一打击者;5例三种打击者预后最差。
要点
- ISS-Ⅲ期合并1q获得/扩增或17p缺失的双/多重打击患者PFS和OS显著缩短。
- 两种及以上打击因素者中位PFS 14.5个月、OS 18.4个月,显著差于单一打击。
- 三种打击因素者仅5例,PFS 0.9~15.1个月、OS 0.9~18.9个月,预后最差。
核心结论
- 基于ISS分期与FISH检测的细胞遗传学异常,携带两种或以上危险因素的双/多重打击NDMM患者预后极差。
研究设计与样本
- 回顾性分析2009年11月至2018年5月就诊的270例初诊多发性骨髓瘤患者临床资料。
- 将ISS-Ⅲ期和HRCA(1q获得/扩增、17p缺失)定义为打击因素,按携带数目分为0至3个危险因素组。
- 应用Kaplan-Meier曲线分析无进展生存(PFS)和总生存(OS)。
主要发现
- 无打击因素组66例(24.4%),中位PFS和OS分别为28.9和53.7个月。
- 一种打击因素组120例(44.4%),中位PFS和OS分别为23.0和42.3个月,与无打击组比较P值均>0.05。
- 两种及以上打击因素组84例(31.1%),中位PFS 14.5个月(HR=1.584,95%CI 1.082~2.319;P=0.003),中位OS 18.4个月(HR=2.299,95%CI 1.485~3.560;P<0.001),均与一种打击因素组比较。
- 三种打击因素者5例(1.9%),PFS 0.9~15.1个月,OS 0.9~18.9个月,较两种打击因素组显著缩短。
- 分析ISS分期与HRCA的不同组合,结果类似。
关键数值与推荐
- 打击因素定义为ISS-Ⅲ期、1q获得/扩增和17p缺失,通过FISH检测细胞遗传学异常。
- 按携带打击因素数目分为0、1、2、3个危险因素组。
- 双/三重打击与单一打击比较:PFS的HR=1.584(95%CI 1.082~2.319,P=0.003),OS的HR=2.299(95%CI 1.485~3.560,P<0.001)。
临床怎么用
- 对初诊多发性骨髓瘤患者应结合ISS分期与FISH检测1q获得/扩增和17p缺失进行风险分层。
- 携带两种及以上打击因素者可识别为高危患者,需更密切监测和强化治疗考虑。
- ISS-Ⅲ期同时携带1q获得/扩增和17p缺失的少数患者可能代表极高危亚组。
局限性
- 为单中心回顾性研究,样本量270例,三种打击因素组仅5例。
- 研究时段为2009年至2018年,治疗方案可能异质。
- 需前瞻性大样本研究验证双/多重打击分层标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the prognostic significance of combining ISS-Ⅲ and high risk cytogenetic abnormalities [HRCAs, including 1q gain/amplification and del (17p) ] in patients with newly-diagnosed multiple myeloma (NDMM) . Methods: The clinical characteristics and relevant variables were retrospectively analyzed in a total of 270 NDMM patients diagnosed between November 2009 and May 2018. ISS-Ⅲ stage and HRCAs [detected by FISH, including 1q gain/amplification and del (17p) ] were defined as risk factors (hit) . Based to the number of hit per case, these patients were divided into four groups carrying 0 to 3 risk factors, respectively. Progress-free survival (PFS) and overall survival (OS) were then analyzed using the Kaplan-Meier estimator. Results: Patients who carried single hit (n=120, 44.4%) had shorter median PFS (23.0 vs 28.9 months; P>0.05) and OS (42.3 vs 53.7 months; P>0.05) than those with no risk factors (n=66, 24.4%) . Of note, the outcome of patients who had two or more risk factors (double/triple, n=84, 31.1%) was much worse than those with either no or one risk factor, indicated by significantly reduced median PFS (14.5 months; HR=1.584, 95%CI 1.082-2.319; P=0.003 for double/triple vs single hit) and OS (18.4 months, HR=2.299, 95%CI 1.485-3.560; P<0.001 for double/triple vs single hit) . Strikingly, patients who had three risk factor (triple hit, n=5, 1.9%) displayed the poorest survival with extraordinarily shorter PFS (0.9-15.1 months) and OS (0.9-18.9 months) compared to those carrying two risk factors (double hit) . Analogous results were obtained when different combinations of ISS stages and HRCAs were analyzed. Conclusion: These results suggest a potential but rather important role of combining multiple (e.g. double or triple) adverse factors determined via the routine ISS staging and FISH detection of cytogenetic abnormalities in risk stratification and prognostic prediction, which might be helpful to identify high risk patients more precisely at diagnosis. It also raised a possibility that a small group of ISS-Ⅲ patients carrying both 1q gain/amplification and del (17p) might represent an "extremely-high risk" subset of MM. 目的: 探讨初诊多发性骨髓瘤(NDMM)患者中ISS-Ⅲ期伴高危细胞遗传学异常(HRCA)1q获得/扩增或17p缺失双重打击的预后意义。 方法: 回顾性分析2009年11月至2018年5月就诊的270例NDMM患者的临床资料,将ISS-Ⅲ期和两种HRCA(1q获得/扩增和17p缺失)定义为打击因素,根据患者携带打击因素的数目分组,应用Kaplan-Meier曲线分析各组无进展生存(PFS)和总生存(OS)时间的差异。 结果: 无打击因素组患者66例(24.4%),中位PFS和OS时间分别为28.9和53.7个月;一种打击因素组120例(44.4%),中位PFS和OS时间分别为23.0个月和42.3个月(P值均>0.05),后者预后较差;与一种打击因素组比较,携带两种及以上打击因素组患者84例(31.1%),中位PFS和OS时间均显著缩短,分别为14.5个月(HR=1.584,95%CI 1.082~2.319;P=0.003)和18.4个月(HR=2.299,95%CI 1.485~3.560;P<0.001);其中5例(1.9%)携带三种打击因素,其PFS时间为0.9~15.1个月,OS时间为0.9~18.9个月,均较携带两种打击因素组显著缩短,预后最差。进一步分析ISS分期与HRCA的不同组合,结果类似。 结论: 基于ISS分期与细胞遗传学异常的FISH检测,携带两种或以上危险因素(包括ISS-Ⅲ期和HRCA)的双/多重打击NDMM患者预后极差。.
引用
- Liu XL, Yang YP, Bai J, et al. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31856439. doi:10.3760/cma.j.issn.0253-2727.2019.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。